Japanese Earnings Roundup: Eisai's Accelerated Perampanel Development Hits The Brakes; Takeda Averts Actos Setbacks For Now
This article was originally published in PharmAsia News
Executive Summary
TOKYO - A busy Friday of quarterly earnings presentations gave a first glimpse of the full impact of the March 11 earthquake and tsunami in Northern Japan. Takeda Pharmaceutical Co. Ltd., Otsuka Holdings Co., Ltd., Daiichi Sankyo Co. Ltd, Mitsubishi Tanabe Pharma Corp. and Dainippon Sumitomo Pharma Co. Ltd. all reported July 29 earnings for the first full quarter since the earthquake, but perhaps the biggest news of the day was an announcement from Eisai Co. Ltd. on a setback to what had been an ambitious drive for a key drug's approval